Defensive Strategy for Downtrend Market The pas
Post# of 24955
(Total Views: 155)
Posted On: 11/09/2022 8:54:51 AM
Defensive Strategy for Downtrend Market
The past months of market volatility has not been kind to many tech and growth sector stocks which has seen large drops between 30-50%. The recent beatdown of these sectors are mainly due to the market uncertainty of growing inflation numbers, quantitative easing of Fed's reserve, Russian-Ukraine War and rise in oil pricing.
The market has diverted its attention from the growth sector and into defensive sectors ie. healthcare, utilities and consumer staple; which are less volatile and less sensitive to the economic cycle. The simple understanding is that these sectors fall under human essential services, necessary for any day to day affair.
Regencell Bioscience Limited’s (NASDAQ:RGC) a bioscience and healthcare company which focuses heavily on R&D and commercialisation of Traditional Chinese Medicine (TCM) treatment specifically ADHD (Attention Deficit Hyperactivity Disorder) and ASD (Autism Spectrum Disorders), and infectious diseases affecting people’s immune system such as COVID.
The company's CEO (Mr. Yat-Gai Au), since IPO day has bought over $5 million of ordinary shares and has not sold any shares despite the having seen the stock price rose staggeringly. The company is currently in the business for the long run and will continue to be vested in its business model of developing treatments for AHDH and ASD as treatment trials are ongoing.
[https://www.valuewalk.com/game-stop-or-game-on-rgc-has-it-all-and-twice-more/]
The past months of market volatility has not been kind to many tech and growth sector stocks which has seen large drops between 30-50%. The recent beatdown of these sectors are mainly due to the market uncertainty of growing inflation numbers, quantitative easing of Fed's reserve, Russian-Ukraine War and rise in oil pricing.
The market has diverted its attention from the growth sector and into defensive sectors ie. healthcare, utilities and consumer staple; which are less volatile and less sensitive to the economic cycle. The simple understanding is that these sectors fall under human essential services, necessary for any day to day affair.
Regencell Bioscience Limited’s (NASDAQ:RGC) a bioscience and healthcare company which focuses heavily on R&D and commercialisation of Traditional Chinese Medicine (TCM) treatment specifically ADHD (Attention Deficit Hyperactivity Disorder) and ASD (Autism Spectrum Disorders), and infectious diseases affecting people’s immune system such as COVID.
The company's CEO (Mr. Yat-Gai Au), since IPO day has bought over $5 million of ordinary shares and has not sold any shares despite the having seen the stock price rose staggeringly. The company is currently in the business for the long run and will continue to be vested in its business model of developing treatments for AHDH and ASD as treatment trials are ongoing.
[https://www.valuewalk.com/game-stop-or-game-on-rgc-has-it-all-and-twice-more/]
(0)
(0)Scroll down for more posts ▼